Table 2.
Mutational analysis of cfDNA.
| Patient#1 | Gene | Draw 4 | Draw 8 | Draw 9 | Draw 10 |
|---|---|---|---|---|---|
| ERBB2 | – | – | S310F (0.18%) | S310F (0.29%) | |
| TP53 | R213* (0.08%) | R213* (0.47%) | R213* (2.91%) | R213* (4.5%) | |
| Patient#2 | Gene | Draw 4 | Draw 6 | ||
| ERBB2 | – | G776V (1.94%) | |||
| Patient#3 | Gene | Draw 1 | Draw 2 | ||
| ERBB2 | – | L755S (0.13%) | |||
| ESR1 | E380Q (0.50%), Y537N (0.33%) | E380Q (0.07%) | |||
| PIK3CA | E545K (2.7%) | E545K (30%), E726K (0.09%) | |||
| TP53 | R248Q (0.31%) | R248Q (0.19%), G245D (0.11%) | |||
| Patient#4 | Gene | Draw 1 | Draw 2 | Draw 4 | |
| ERBB2 | L755S (0.79%), V777L (0.93%) | – | L755S (0.78%), V777L (0.46%) | ||
| PIK3CA | H1047R (1.03%) | – | H1047R (0.58%) | ||
| TP53 | H365fs (0.38%) | – | – | ||
| Patient#5 | Gene | Draw 1 | |||
| ERBB2 | L755S (14.39%) |
Oncomine cfDNA Assay v2 detects hotspot mutations in the cfDNA of BC patients. (−): no mutations detected. Variant allele frequency is provided in parentheses (%).
*Indicates a termination codon.